DK324385D0 - Farmaceutisk praeparat med kontrolleret frigivelse af det aktive stof - Google Patents

Farmaceutisk praeparat med kontrolleret frigivelse af det aktive stof

Info

Publication number
DK324385D0
DK324385D0 DK324385A DK324385A DK324385D0 DK 324385 D0 DK324385 D0 DK 324385D0 DK 324385 A DK324385 A DK 324385A DK 324385 A DK324385 A DK 324385A DK 324385 D0 DK324385 D0 DK 324385D0
Authority
DK
Denmark
Prior art keywords
active substance
controlled release
pharmaceutical preparation
pharmaceutical
preparation
Prior art date
Application number
DK324385A
Other languages
English (en)
Other versions
DK324385A (da
Inventor
Yegnaswami Raghunathan
Original Assignee
Pennwalt Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pennwalt Corp filed Critical Pennwalt Corp
Publication of DK324385D0 publication Critical patent/DK324385D0/da
Publication of DK324385A publication Critical patent/DK324385A/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5036Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK324385A 1984-07-18 1985-07-17 Farmaceutisk praeparat med kontrolleret frigivelse af det aktive stof DK324385A (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63197984A 1984-07-18 1984-07-18

Publications (2)

Publication Number Publication Date
DK324385D0 true DK324385D0 (da) 1985-07-17
DK324385A DK324385A (da) 1986-01-19

Family

ID=24533574

Family Applications (1)

Application Number Title Priority Date Filing Date
DK324385A DK324385A (da) 1984-07-18 1985-07-17 Farmaceutisk praeparat med kontrolleret frigivelse af det aktive stof

Country Status (11)

Country Link
EP (1) EP0171528A3 (da)
JP (1) JPH0649645B2 (da)
KR (1) KR920007568B1 (da)
AU (1) AU571659B2 (da)
CA (1) CA1236023A (da)
DK (1) DK324385A (da)
FI (1) FI852804L (da)
NO (1) NO852880L (da)
NZ (1) NZ211449A (da)
PH (1) PH20391A (da)
ZA (1) ZA853462B (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0248051A1 (en) * 1985-11-29 1987-12-09 FISONS plc Pharmaceutical composition including sodium cromoglycate
US4859462A (en) * 1986-07-30 1989-08-22 Fisons Corporation Polymer-treated ion exchange resins
NZ219925A (en) * 1986-07-30 1989-06-28 Pennwalt Corp Polymer-treated sulphonic acid cationic exchange resin particles
US4859461A (en) * 1986-07-30 1989-08-22 Fisons Corporation Coatable ion exchange resins
IE62100B1 (en) * 1986-07-30 1994-12-14 Fisons Corp Coated ion exchange resins
US4895723A (en) * 1986-09-08 1990-01-23 Amer And Company Cholestyramine compositions and method for preparation thereof
DE3719764A1 (de) * 1987-06-13 1988-12-22 Bayer Ag Ionenaustauscherharze beladen mit chinoloncarbonsaeurederivaten, ihre herstellung und verwendung
US4996047A (en) * 1988-11-02 1991-02-26 Richardson-Vicks, Inc. Sustained release drug-resin complexes
US4999189A (en) * 1988-11-14 1991-03-12 Schering Corporation Sustained release oral suspensions
US5186930A (en) * 1988-11-14 1993-02-16 Schering Corporation Sustained release oral suspensions
US5149523A (en) * 1989-06-20 1992-09-22 Aktiebolaget Hassle Polystyrenesulfonate-drug complex and solid dosage forms thereof
IT1241417B (it) 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
JP3286315B2 (ja) * 1990-06-20 2002-05-27 アドバンスト ポリマー システムズ,インコーポレイティド 可溶性活性物質の調節された放出のための組成物及び方法
EP0563294A1 (en) * 1990-12-21 1993-10-06 Richardson-Vicks, Inc. Polyamine drug-resin complexes
JP3278192B2 (ja) * 1992-04-03 2002-04-30 ロート製薬株式会社 徐放性液剤
US5350584A (en) * 1992-06-26 1994-09-27 Merck & Co., Inc. Spheronization process using charged resins
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
CA2509429A1 (en) 2002-11-26 2004-06-10 University Of Maryland, Baltimore Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
EP2361612A3 (en) * 2005-06-09 2011-10-12 Upm Pharmaceuticals, Inc. Aqueous sustained-release drug delivery system for highly water-soluble electrolytic drugs
CA2757337A1 (en) 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition
ES2471340B1 (es) 2012-12-21 2015-08-17 Laboratorios Rubió, S.A. Composición farmacéutica oral para fármacos de elevada posología
ES2470940B1 (es) * 2012-12-21 2015-04-16 Laboratorios Rubió, S.A. Aducto entre un poliol y una resina de intercambio iónico

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2990332A (en) * 1958-04-02 1961-06-27 Wallace & Tiernan Inc Pharmaceutical preparations comprising cation exchange resin adsorption compounds and treatment therewith
DE2246037B2 (de) * 1972-09-20 1975-02-27 Taeschner & Co, 8831 Kipfenberg Peroral anwendbares Arzneimittel mit verzögerter Resorbierbarkeit in Suspensionsform
CA1086226A (en) * 1976-11-26 1980-09-23 Yegnaswami Raghunathan Ion exchange resin prolonged release pharmaceutical preparations
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations

Also Published As

Publication number Publication date
AU571659B2 (en) 1988-04-21
AU3963585A (en) 1986-01-23
JPH0649645B2 (ja) 1994-06-29
DK324385A (da) 1986-01-19
KR920007568B1 (ko) 1992-09-07
KR860000865A (ko) 1986-02-20
EP0171528A2 (en) 1986-02-19
ZA853462B (en) 1985-12-24
PH20391A (en) 1986-12-10
FI852804L (fi) 1986-01-19
JPS6130514A (ja) 1986-02-12
NO852880L (no) 1986-01-20
NZ211449A (en) 1987-08-31
FI852804A0 (fi) 1985-07-17
EP0171528A3 (en) 1986-04-23
CA1236023A (en) 1988-05-03

Similar Documents

Publication Publication Date Title
DK324385A (da) Farmaceutisk praeparat med kontrolleret frigivelse af det aktive stof
DK158032C (da) Polydepotpraeparat med kontrolleret afgivelse af aktivt stof og fremgangsmaade til fremstilling af dette polydepotpraeparat
DK494782A (da) Kapsel med langvarig frigoerelse af aktivt stof til droevtyggere
DK158770C (da) Anvendelse af paroxetin til fremstilling af medikament mod fedme
DK178285D0 (da) Catecholamin-holdig intranasal laegemiddelformulering med forsinket frigivelse af den aktive bestanddel
NO862956D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidin-derivater.
DK147386D0 (da) Derivater af methylen-bisphosphonsyre, fremgangsmaade til fremstillingaf samme samt farmaceutisk sammensaetning
DK386986A (da) Injicerbar halvfast farmaceutisk formulering med langsom frigivelse af den aktive bestanddel
NO171592C (no) Fremgangsmaate for fremstilling av aktive cinnolin-derivater
DK106685D0 (da) Kontrolleret afgivelse af virksomt stof samt fremgangsmaade til fremstilling deraf
DK165984C (da) Fremgangsmaade til fremstilling af sphingosinderivater
NO862741D0 (no) Gjoedsel med kontrollert frigivning av urea.
DK524489D0 (da) Fremgangsmaade til fremstilling af biologisk aktive forbindelser, specielt enzymer
DK73980A (da) Insecticidt eller nematodicidt granulat med forhalet frigoerelse af den aktive bestanddel
DK38493A (da) Fremgangsmaade til fremstilling af alkoxymethylether- og alkoxymethylesterderivater af glyceroler
GB2181053B (en) Pharmaceutical formulations with controlled release of the active substance
DK516286A (da) Fremgangsmaade til fremstilling af oxazolderivater
DK414180A (da) Fremgangsmaade til fremstilling af dibenzazepinderivater
DK115291A (da) Fremgangsmaade til fremstilling af amfotere overfladeaktive imidazolinderivater
DK464686D0 (da) Praeparat med kontrolleret afgivelse af det aktive stof
DK158224C (da) Fremgangsmaade til fremstilling af indolderivater
DK163980A (da) Fremgangsmaade til fremstilling af et biologisk aktivt stof 41.200rp med immunstimulerende virkning
DK206985A (da) Transdermal doseringsform med forbedret gennemtraengning af det aktive stof
DK258886A (da) Fremgangsmaade til fremstilling af alkyloxiraner
DK509986A (da) Fremgangsmaade til fremstilling af aryl-cyanamider

Legal Events

Date Code Title Description
AHB Application shelved due to non-payment